Shai Shimony , MD, Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy of triplet combinations in FLT3-mutated acute myeloid leukemia (AML), both in the frontline setting and in the relapsed/refractory (R/R) setting. Dr Shimony also highlights the importance of obtaining longer follow-up data on these combinations to better understand durability of response. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.